Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Quality of life differences between responders and nonresponders in the treatment of cutaneous lupus erythematosus.

Literature DB >> 23324773

Quality of life differences between responders and nonresponders in the treatment of cutaneous lupus erythematosus.

Aileen Y Chang¹, Elizabeth Ghazi, Joyce Okawa, Victoria P Werth.

Abstract

Entities: Chemical Disease Species

Mesh：

Year: 2013 PMID： 23324773 PMCID： PMC3928008 DOI： 10.1001/2013.jamadermatol.467

Source DB: PubMed Journal: JAMA Dermatol ISSN： 2168-6068 Impact factor: 10.282

× No keyword cloud information.

5 in total

1. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus.

Authors: Joerg Albrecht; Lynne Taylor; Jesse A Berlin; Samuel Dulay; Gina Ang; Steven Fakharzadeh; Jonathan Kantor; Ellen Kim; Giuseppe Militello; Karen McGinnis; Stephen Richardson; James Treat; Carmela Vittorio; Abby Van Voorhees; Victoria P Werth
Journal: J Invest Dermatol Date: 2005-11 Impact factor: 8.551

2. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases.

Authors: M M Chren; R J Lasek; S A Flocke; S J Zyzanski
Journal: Arch Dermatol Date: 1997-11

3. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.

Authors: Aileen Y Chang; Evan W Piette; Kristen P Foering; Thomas R Tenhave; Joyce Okawa; Victoria P Werth
Journal: Arch Dermatol Date: 2011-07-18

4. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus.

Authors: Rachel Klein; Siamak Moghadam-Kia; Jonathan LoMonico; Joyce Okawa; Chris Coley; Lynne Taylor; Andrea B Troxel; Victoria P Werth
Journal: Arch Dermatol Date: 2011-02

5. Quality of life in cutaneous lupus erythematosus.

Authors: Rachel Klein; Siamak Moghadam-Kia; Lynne Taylor; Christopher Coley; Joyce Okawa; Jonathan LoMonico; Mary-Margaret Chren; Victoria P Werth
Journal: J Am Acad Dermatol Date: 2011-03-12 Impact factor: 11.527

5 in total

14 in total

Review 1. Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects.

Authors: Joshua Chang; Victoria P Werth
Journal: Expert Rev Clin Immunol Date: 2016-06-01 Impact factor: 4.473

2. Factors associated with quality of life in cutaneous lupus erythematosus using the Revised Wilson and Cleary Model.

Authors: Motolani E Ogunsanya; Sung Kyung Cho; Andrew Hudson; Benjamin F Chong
Journal: Lupus Date: 2020-09-03 Impact factor: 2.911

3. Validation and reliability of a disease-specific quality-of-life measure in patients with cutaneous lupus erythematosus.

Authors: M E Ogunsanya; S K Cho; A Hudson; B F Chong
Journal: Br J Dermatol Date: 2019-04-07 Impact factor: 9.302

4. Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life.

Authors: E S Robinson; R Feng; J Okawa; V P Werth
Journal: Br J Dermatol Date: 2014-11-30 Impact factor: 9.302

5. Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials.

Authors: Majid Zeidi; Kristen L Chen; Jay Patel; Krisha Desai; Hee Joo Kim; Srita Chakka; Rachel Lim; Victoria P Werth
Journal: Lupus Date: 2022-03-08 Impact factor: 2.911

Quality of life differences between responders and nonresponders in the treatment of cutaneous lupus erythematosus.

1. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus.

2. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases.

3. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.

4. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus.

5. Quality of life in cutaneous lupus erythematosus.

Review 1. Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects.

2. Factors associated with quality of life in cutaneous lupus erythematosus using the Revised Wilson and Cleary Model.

3. Validation and reliability of a disease-specific quality-of-life measure in patients with cutaneous lupus erythematosus.

4. Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life.

5. Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials.

Review 6. Cutaneous lupus erythematosus: diagnosis and treatment.

Review 7. Practice and Educational Gaps in Lupus, Dermatomyositis, and Morphea.

Review 8. Update on pathogenesis and treatment of CLE.

Review 9. Immunogenetics of cutaneous lupus erythematosus.

10. Measurement of disease severity in cutaneous autoimmune diseases.